Difference between revisions of "Columbia Technology Ventures"

From WikiCU
Jump to: navigation, search
Line 1: Line 1:
−
'''Science and Technology Ventures''' is responsible for managing the transition of Columbia's intellectual property (patents, copyrights, trademarks) from academia to industry. STV works closely with Columbia's faculty to bridge their work with the corporate world, entrepreneurs and investors. Since Columbia University is a non-profit and a teaching and research institution, a great many fantastic ideas and inventions are produced on a regular basis but the University can not as part of its mission bring this innovation to the outside world directly.  Instead, STV partners with a commercial partner to adapt University technology for the benefit of society through various means, such as startup company spinoffs, inclusion of Columbia technology as important product features and more.  One positive side-benefit of this includes revenue generation from intellectual property.  
+
Columbia Technology Ventures [http://www.techventures.columbia.edu], also known as Tech Ventures, is the technology transfer office of Columbia University [http://www.columbia.edu]. Columbia University is widely recognized by industry as one of the best sources of scientific innovation, and its technology transfer operation has consistently ranked in the top five of universities for the past decade(measured by annual licensing revenues).
  
−
Columbia University is recognized by industry as one of the best sources of adaptable innovation in the country, and consistently ranks in the top three by revenues on licenses year over year for the past decade.
+
Columbia University is a non-profit teaching and research institution, and is not in the business of developing, manufacturing, and selling commercial products. Instead, through the Columbia Technology Ventures office, Columbia works with commercial partners to develop, adapt, and apply University technology for the benefit of society. Commonly, this is done by licensing technologies to industrial partners who wish to develop products or services based on those technologies.  In certain situations, it's more appropriate to create a spin-off to bring a technology to market.  Columbia Technology Ventures, through its Venture Lab program, provides advisory and other resources to faculty, staff, and students around etnrepreneurial and start-up activity. On average, the office triages more than 300 new invention disclosures from, executes 50-60 license deals, and helps launch 10-12 start-ups each year.
  
−
[[Richard Axel]]'s patent is the richest patent in higher education history.
+
A side-benefit of this licensing and start-up activity is the generation of revenues, which are shared between the inventors and the university. Columbia has reinvested these proceeds into recruiting new faculty, building new research programs and departments, and upgrading and expanding campus facilities.  According to the Association of University Technology Managers (AUTM) 2007 Survey, Columbia University received approximately $136M in annual licensing revenues.
 +
 
 +
Columbia’s inventions are behind several well-known biopharmaceutical products, including Remicade; ReoPro; Tysabri; Erbitux; Simponi; Zolinza; Synagis; Xalatan / Xalcom; Epogen; Avonex; and Herceptin, as well as consumer products, including the Apple iPhone/iTouch, DVDs, LCDs, VOIP, video-on-demand, and HDTV.
 +
 
 +
Columbia Technology Ventures employs 49 full-time staff, including 11 PhDs, 8 JDs, and 7 MBAs, at two offices, on Columbia’s Morningside and Medical Center campuses.  Columbia Technology Ventures also has a popular program for Columbia graduate students, called the Fellows Program.  Through the Program, students gain a solid introduction to and experience with technology transfer while supporting technology marketing activities, e.g. market research/diligence, business planning, technology marketing, etc.
 +
 
 +
Columbia Technology Ventures has gone through several name changes over the years (formerly known as Science & Technology Ventures (STV), Columbia Innovation Enterprise (CIE), and Office of Science & Technology Development (OSTD)).  The office reports into the Office of the Executive Vice President (Robert Kasdin).  Orin Herskowitz is the current Executive Director of Columbia Technology Ventures.  Previous Executive Directors include Michael Cleare, and Jack Granowitz.
 +
 
 +
Columbia Technology Ventures has a general mailbox for inquiries: http:\\www.techventures.columbia.edu.
  
−
[[Orin Herskowitz]] is Chief Operating Officer for Science and Technology Ventures. [http://stv.columbia.edu/index.php?option=com_content&task=view&id=49&Itemid=69]
 
  
 
== External links ==
 
== External links ==
−
* [http://www.stv.columbia.edu/ Science and Technology Ventures Site]
+
* [http://www.techventures.columbia.edu/ Columbia Technology Ventures website]
 
* [http://media.www.columbiaspectator.com/media/storage/paper865/news/2006/11/28/News/Patents.Bring.In.The.Cash.To.Columbia-2509908.shtml Patents Bring in the Cash to Columbia] - [[Columbia Daily Spectator|The Spectator]] ''11-28-06''
 
* [http://media.www.columbiaspectator.com/media/storage/paper865/news/2006/11/28/News/Patents.Bring.In.The.Cash.To.Columbia-2509908.shtml Patents Bring in the Cash to Columbia] - [[Columbia Daily Spectator|The Spectator]] ''11-28-06''
  
 
[[Category:University components]]
 
[[Category:University components]]

Revision as of 13:59, 19 September 2009

Columbia Technology Ventures [1], also known as Tech Ventures, is the technology transfer office of Columbia University [2]. Columbia University is widely recognized by industry as one of the best sources of scientific innovation, and its technology transfer operation has consistently ranked in the top five of universities for the past decade(measured by annual licensing revenues).

Columbia University is a non-profit teaching and research institution, and is not in the business of developing, manufacturing, and selling commercial products. Instead, through the Columbia Technology Ventures office, Columbia works with commercial partners to develop, adapt, and apply University technology for the benefit of society. Commonly, this is done by licensing technologies to industrial partners who wish to develop products or services based on those technologies. In certain situations, it's more appropriate to create a spin-off to bring a technology to market. Columbia Technology Ventures, through its Venture Lab program, provides advisory and other resources to faculty, staff, and students around etnrepreneurial and start-up activity. On average, the office triages more than 300 new invention disclosures from, executes 50-60 license deals, and helps launch 10-12 start-ups each year.

A side-benefit of this licensing and start-up activity is the generation of revenues, which are shared between the inventors and the university. Columbia has reinvested these proceeds into recruiting new faculty, building new research programs and departments, and upgrading and expanding campus facilities. According to the Association of University Technology Managers (AUTM) 2007 Survey, Columbia University received approximately $136M in annual licensing revenues.

Columbia’s inventions are behind several well-known biopharmaceutical products, including Remicade; ReoPro; Tysabri; Erbitux; Simponi; Zolinza; Synagis; Xalatan / Xalcom; Epogen; Avonex; and Herceptin, as well as consumer products, including the Apple iPhone/iTouch, DVDs, LCDs, VOIP, video-on-demand, and HDTV.

Columbia Technology Ventures employs 49 full-time staff, including 11 PhDs, 8 JDs, and 7 MBAs, at two offices, on Columbia’s Morningside and Medical Center campuses. Columbia Technology Ventures also has a popular program for Columbia graduate students, called the Fellows Program. Through the Program, students gain a solid introduction to and experience with technology transfer while supporting technology marketing activities, e.g. market research/diligence, business planning, technology marketing, etc.

Columbia Technology Ventures has gone through several name changes over the years (formerly known as Science & Technology Ventures (STV), Columbia Innovation Enterprise (CIE), and Office of Science & Technology Development (OSTD)). The office reports into the Office of the Executive Vice President (Robert Kasdin). Orin Herskowitz is the current Executive Director of Columbia Technology Ventures. Previous Executive Directors include Michael Cleare, and Jack Granowitz.

Columbia Technology Ventures has a general mailbox for inquiries: http:\\www.techventures.columbia.edu.


External links

Retrieved from "https://www.wikicu.com/index.php?title=Columbia_Technology_Ventures&oldid=30072"